2010 Award of Excellence Dr. Brian O’Rourke, President and CEO of the Canadian Agency for Drugs and Technologies in Health (CADTH), is pleased to announce that Dr. Andreas Laupacis, MD, MSc, FRCPC, is the inaugural recipient of the Jill M. Sanders Award of Excellence in Health Technology Assessment (HTA). “Dr. Laupacis is a nationally and inte...
CADTH is committed to continuous improvement and transparency. Here you will find evaluations of CADTH and specific CADTH initiatives, as well as responses to the evaluations. 2016 Science-Metrix Evaluation of CADTH 2016 Science-Metrix Evaluation of CADTH - Management Response 2016 Application Fees Administrative Review 2015 MEDLIOR H...
As was announced in May 2014, CADTH will be implementing an application fee for manufacturer applications filed with the CADTH pan-Canadian Oncology Drug Review (pCODR). It is proposed that all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with conditions (NOC/c) date of April 1, 2015 or la...
CADTH operates two pan-Canadian drug review processes: the CADTH pan-Canadian Oncology Drug Review (pCODR), which deals specifically with cancer drugs, and the CADTH Common Drug Review (CDR), which deals with other drugs. Both pCODR and CDR are designed to bring consistency and clarity to the assessment of drugs in Canada by reviewing clinical...
pCODR Communication Updates Drug Review Updates Provincial Funding Summary (iJODR) Cancer Drug Pipeline Information pCODR Performance Report